Skip to main content
Premium Trial:

Request an Annual Quote

Roche-Illumina News Takes Over Twitter

When Roche yesterday announced its $5.7 billion hostile takeover bid for Illumina, reactions on Twitter were varied and swift, ranging from the humorous — like Stuart Glenn's depiction of what a potential acquisition might be like — to the concerned — "If Roche plans to do to DNA sequencing what it did to PCR, then a lot of genomicists are going to need second jobs," Misha Angrist says — to the optimistic — "More evidence that big pharma is getting ready for personalised med?" James Gazzard asks of the potential deal. Dan Vorhaus summarizes the news simply, tweeting that the "message coming out of Roche seems heavily focused on Dx [diagnostics] development [and] access, not so much technology development."

As our sister publication GenomeWeb Daily News reports, Illumina's board of directors has responded to Roche's bid by adopting a poison pill provision. According to GWDN, Illumina made this move in order to deter what it called "coercive and otherwise unfair takeover tactics" on the part of Roche.

In response to this most recent news, Peter Roberts tweets: "Interesting to see [how] this fight is developing!"

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.